Study aim: Evaluation the effect of crocetin in improving the clinical and laboratory symptoms of patients with COVID-19 Design: A randomized, blinded, placebo-controlled clinical trial with a parallel-group design of 40 patients, randomizing with the table of random numbers. Settings and conduct: This study will be performed on outpatients. In this study, 40 patients with COVID-19 disease were selected and randomly assigned to two groups of 20 individuals. Patients in the standard diet control group will receive standard coronavirus treatment with a placebo. In addition to the standard diet, patients in the treatment group will be treated with 7.5 mg of crocetin three times a day for at least 2 weeks. Patients are monitored at intervals of 3 days, 1 week and 2 weeks after receiving the drug or placebo in terms of time interval until clinical and laboratory symptoms improve. Participants/Inclusion and exclusion criteria: People over 18 years of age with a diagnosis of coronavirus based on clinical and laboratory symptoms; home quarantine and outpatients Intervention groups: The control group receives standard anti-coronavirus drugs with placebo. In addition to the common anti coronavirus drugs, the treatment group also receives crocetin capsules. Main outcome variables: Time interval until lymphopenia improves Time interval until CRP normalizes Time interval until clinical symptoms improve (fever, cough, and myalgia)